A fate worse than death: apoptosis as an oncogenic process
暂无分享,去创建一个
[1] O. Bairey,et al. Bcl-2, Bcl-X, Bax, and Bak expression in short- and long-lived patients with diffuse large B-cell lymphomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] M. Maiuri,et al. BAX and BAK1 are dispensable for ABT-737-induced dissociation of the BCL2-BECN1 complex and autophagy , 2015, Autophagy.
[3] Philip Levy Ho,et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance , 2014, Nature.
[4] D. Vaux,et al. Prosurvival Bcl-2 family members affect autophagy only indirectly, by inhibiting Bax and Bak , 2014, Proceedings of the National Academy of Sciences.
[5] S. Nagata,et al. [Apoptosis and autoimmune diseases]. , 1993, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.
[6] D. Green,et al. Mitochondria and cell death: outer membrane permeabilization and beyond , 2010, Nature Reviews Molecular Cell Biology.
[7] Christine Feig,et al. CD95/Fas promotes tumour growth , 2010, Nature.
[8] L. Liu,et al. Nucleolytic Cleavage of the Mixed Lineage Leukemia Breakpoint Cluster Region during Apoptosis* , 2001, The Journal of Biological Chemistry.
[9] C. Rauch,et al. Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.
[10] D. Lauffenburger,et al. Quantitative analysis of pathways controlling extrinsic apoptosis in single cells. , 2008, Molecular cell.
[11] J. Martinou,et al. Phosphorylation of bid by casein kinases I and II regulates its cleavage by caspase 8. , 2001, Molecular cell.
[12] A. Strasser,et al. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis , 2009, Cell Death and Differentiation.
[13] A. Mills,et al. Getting around lethality with inducible Cre-mediated excision. , 2002, Seminars in cell & developmental biology.
[14] Rebecca C Taylor,et al. Apoptosis: controlled demolition at the cellular level , 2008, Nature Reviews Molecular Cell Biology.
[15] Michael T. Certo,et al. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. , 2007, The Journal of clinical investigation.
[16] C. Osborne,et al. bcl‐2 and apoptosis in lymph node positive breast carcinoma , 1998, Cancer.
[17] J. Martinez-Climent,et al. Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. , 2014, Blood.
[18] S. Lowe,et al. Genetic analysis of chemoresistance in primary murine lymphomas , 2000, Nature Medicine.
[19] S. Pai,et al. Apoptosis index is a predictor of metastatic phenotype in patients with early stage squamous carcinoma of the tongue , 2001, Cancer.
[20] A. Letai,et al. Diagnosing and exploiting cancer's addiction to blocks in apoptosis , 2008, Nature Reviews Cancer.
[21] R. Weissleder,et al. In vivo imaging of drug-induced mitochondrial outer membrane permeabilization at single-cell resolution. , 2012, Cancer research.
[22] G. Barber,et al. Diverse roles of STING-dependent signaling on the development of cancer , 2015, Oncogene.
[23] J. D. Jong,et al. Number of apoptotic cells as a prognostic marker in invasive breast cancer , 2000, British Journal of Cancer.
[24] G. Krumschnabel,et al. Apoptosis of leukocytes triggered by acute DNA damage promotes lymphoma formation. , 2010, Genes & development.
[25] J. Prehn,et al. Central roles of apoptotic proteins in mitochondrial function , 2013, Oncogene.
[26] R. Medema,et al. Intravital FRET Imaging of Tumor Cell Viability and Mitosis during Chemotherapy , 2013, PloS one.
[27] Jeffrey W Pollard,et al. Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.
[28] B. Hyman,et al. Apoptotic and non-apoptotic roles of caspases in neuronal physiology and pathophysiology , 2012, Nature Reviews Neuroscience.
[29] A. Hall,et al. Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. , 1999, Blood.
[30] R. Schreiber,et al. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.
[31] R. Medzhitov,et al. p53-mediated hematopoietic stem and progenitor cell competition. , 2010, Cell stem cell.
[32] Erik Sahai,et al. Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity , 2015, Cell.
[33] M. Diaz,et al. Apoptotic stimuli initiate MLL-AF9 translocations that are transcribed in cells capable of division. , 2003, Cancer research.
[34] Jun R Huh,et al. Compensatory Proliferation Induced by Cell Death in the Drosophila Wing Disc Requires Activity of the Apical Cell Death Caspase Dronc in a Nonapoptotic Role , 2004, Current Biology.
[35] R. Larson,et al. Therapy-related myeloid leukemia. , 2008, Seminars in oncology.
[36] I. Ellis,et al. Evidence that the p53 negative / Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: A tissue microarray study of 460 patients , 2005, World journal of surgical oncology.
[37] Markus Rehm,et al. Real-time single cell analysis of Smac/DIABLO release during apoptosis , 2003, The Journal of cell biology.
[38] Matthew E. Ritchie,et al. Apoptotic Caspases Suppress mtDNA-Induced STING-Mediated Type I IFN Production , 2014, Cell.
[39] C. Gregory,et al. Cell death in the neighbourhood: direct microenvironmental effects of apoptosis in normal and neoplastic tissues , 2011, The Journal of pathology.
[40] Karen Cichowski,et al. Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy , 2015, Cell.
[41] G. Evan,et al. Bcl-xL gain of function and p19 ARF loss of function cooperate oncogenically with Myc in vivo by distinct mechanisms. , 2006, Cancer cell.
[42] M. Peter,et al. Death induced by CD95 or CD95 ligand elimination. , 2014, Cell reports.
[43] A. Kimchi,et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 , 1991, Nature.
[44] M. Linhoff,et al. Decreased apoptosome activity with neuronal differentiation sets the threshold for strict IAP regulation of apoptosis , 2004, The Journal of cell biology.
[45] M. Karin,et al. Immunity, Inflammation, and Cancer , 2010, Cell.
[46] E. Warlick. Epidemiology of myelodysplastic syndromes: many questions remain , 2011, Leukemia & lymphoma.
[47] M. Smyth,et al. Immune surveillance of tumors. , 2007, The Journal of clinical investigation.
[48] F. Roviello,et al. Bcl-2 expression correlates with lymphovascular invasion and long-term prognosis in breast cancer , 2006, Breast Cancer Research and Treatment.
[49] G. Atsumi,et al. Fas-induced Arachidonic Acid Release Is Mediated by Ca2+-independent Phospholipase A2 but Not Cytosolic Phospholipase A2, Which Undergoes Proteolytic Inactivation* , 1998, The Journal of Biological Chemistry.
[50] D. Green,et al. Means to an end : apoptosis and other cell death mechanisms , 2011 .
[51] A. Strasser,et al. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2 , 1990, Nature.
[52] S. Fulda,et al. Targeting IAP proteins for therapeutic intervention in cancer , 2012, Nature Reviews Drug Discovery.
[53] Takamitsu A Kato,et al. Caspase-3 promotes genetic instability and carcinogenesis. , 2015, Molecular cell.
[54] James A. Wells,et al. Small-Molecule Activators of a Proenzyme , 2009, Science.
[55] A. Kraft,et al. The BH3 mimetic ABT-737 induces cancer cell senescence. , 2011, Cancer research.
[56] Flore Kruiswijk,et al. p53 in survival, death and metabolic health: a lifeguard with a licence to kill , 2015, Nature Reviews Molecular Cell Biology.
[57] T. Kipps,et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. , 2016, The New England journal of medicine.
[58] M. Peter,et al. The role of CD95 and CD95 ligand in cancer , 2015, Cell Death and Differentiation.
[59] Hyung Don Ryoo,et al. Apoptotic cells can induce compensatory cell proliferation through the JNK and the Wingless signaling pathways. , 2004, Developmental cell.
[60] H. Wajant,et al. Mutant PIK3CA licenses TRAIL and CD95L to induce non-apoptotic caspase-8-mediated ROCK activation , 2010, Cell Death and Differentiation.
[61] M. Redondo,et al. The role and prognostic value of apoptosis in colorectal carcinoma , 2013, BMC Clinical Pathology.
[62] Xiaodong Wang,et al. Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors , 1998, Cell.
[63] Michael T. Lotze,et al. Inflammation and necrosis promote tumour growth , 2004, Nature Reviews Immunology.
[64] L. Moretti,et al. M867, a Novel Selective Inhibitor of Caspase-3 Enhances Cell Death and Extends Tumor Growth Delay in Irradiated Lung Cancer Models , 2008, PloS one.
[65] J. Spychała. Tumor-promoting functions of adenosine. , 2000, Pharmacology & therapeutics.
[66] S. Tait,et al. Mitochondrial apoptosis: killing cancer using the enemy within , 2015, British Journal of Cancer.
[67] G. Ying,et al. Visualization of caspase-3-like activity in cells using a genetically encoded fluorescent biosensor activated by protein cleavage , 2013, Nature Communications.
[68] Karen Blyth,et al. Limited Mitochondrial Permeabilization Causes DNA Damage and Genomic Instability in the Absence of Cell Death , 2015, Molecular cell.
[69] G. Barber,et al. Inflammation-driven carcinogenesis is mediated through STING , 2014, Nature Communications.
[70] C. Berens,et al. UVB-irradiated apoptotic cells induce accelerated growth of co-implanted viable tumor cells in immune competent mice , 2013, Autoimmunity.
[71] Peter E. Czabotar,et al. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy , 2013, Nature Reviews Molecular Cell Biology.
[72] Xiaomei Ma. Epidemiology of myelodysplastic syndromes. , 2012, The American journal of medicine.
[73] S. Armstrong,et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. , 2006, Cancer cell.
[74] Dana M. Brantley-Sieders,et al. Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution. , 2014, The Journal of clinical investigation.
[75] S. Nagata,et al. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD , 1998, Nature.
[76] Fang Li,et al. Apoptotic Cells Activate the “Phoenix Rising” Pathway to Promote Wound Healing and Tissue Regeneration , 2010, Science Signaling.
[77] S. Meterissian,et al. Bcl-2 Is a Useful Prognostic Marker in Dukes’ B Colon Cancer , 2001, Annals of Surgical Oncology.
[78] A. Wyllie. The biology of cell death in tumours. , 1985, Anticancer research.
[79] H. Steller,et al. Programmed Cell Death in Animal Development and Disease , 2011, Cell.
[80] A. Strasser,et al. PUMA promotes apoptosis of hematopoietic progenitors driving leukemic progression in a mouse model of myelodysplasia , 2016, Cell Death and Differentiation.
[81] A. Jimeno,et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy , 2011, Nature Medicine.
[82] Jacco van Rheenen,et al. Imaging hallmarks of cancer in living mice , 2014, Nature Reviews Cancer.
[83] D. Hume,et al. Oncogenic Properties of Apoptotic Tumor Cells in Aggressive B Cell Lymphoma , 2015, Current Biology.
[84] D. Colin,et al. Cellular responses to a prolonged delay in mitosis are determined by a DNA damage response controlled by Bcl-2 family proteins , 2015, Open Biology.
[85] J. Werner,et al. Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis. , 2015, Cancer cell.
[86] M. Rehm,et al. Real Time Analysis of Tumor Necrosis Factor-related Apoptosis-inducing Ligand/Cycloheximide-induced Caspase Activities during Apoptosis Initiation* , 2008, Journal of Biological Chemistry.
[87] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[88] Mark A. Hall,et al. Selection against PUMA Gene Expression in Myc-Driven B-Cell Lymphomagenesis , 2008, Molecular and Cellular Biology.
[89] G. Morata,et al. Caspase inhibition during apoptosis causes abnormal signalling and developmental aberrations in Drosophila , 2004, Development.
[90] S. Tait,et al. Multiple functions of BCL-2 family proteins. , 2013, Cold Spring Harbor perspectives in biology.
[91] M. Peter,et al. The role of CD95 and CD95 ligand in cancer , 2015, Cell Death and Differentiation.
[92] Y. Matsuzaki,et al. Prognostic significance of bcl-2 expression in resected pN2 non-small cell lung cancer. , 2003, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[93] G. Evan,et al. Cooperative interaction between c-myc and bcl-2 proto-oncogenes , 1992, Nature.
[94] G. Trinchieri. Cancer and inflammation: an old intuition with rapidly evolving new concepts. , 2012, Annual review of immunology.
[95] Michael R. Elliott,et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance , 2009, Nature.
[96] S. Nagata. Apoptosis and autoimmune diseases , 2010, Annals of the New York Academy of Sciences.
[97] Baocun Sun,et al. Extent, relationship and prognostic significance of apoptosis and cell proliferation in synovial sarcoma , 2006, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[98] Mark P. Mattson,et al. Apoptosis in neurodegenerative disorders , 2000, Nature Reviews Molecular Cell Biology.
[99] S. Korsmeyer,et al. Antiapoptotic BCL-2 is required for maintenance of a model leukemia. , 2004, Cancer cell.
[100] Laura H. Tang,et al. Bcl-xL promotes metastasis independent of its anti-apoptotic activity , 2016, Nature Communications.
[101] F M Blows,et al. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received , 2010, British Journal of Cancer.
[102] M. Manns,et al. The BH3‐only protein BID impairs the p38‐mediated stress response and promotes hepatocarcinogenesis during chronic liver injury in mice , 2015, Hepatology.
[103] D. Green,et al. Mito-priming as a method to engineer Bcl-2 addiction , 2016, Nature Communications.
[104] Junying Yuan,et al. Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.
[105] S. Korsmeyer,et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.
[106] S. Cory,et al. The Bcl-2 apoptotic switch in cancer development and therapy , 2007, Oncogene.
[107] L. Tanoue,et al. High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology , 2010, BMC Cancer.
[108] Y. Xiong,et al. The E3 ligase PARC mediates the degradation of cytosolic cytochrome c to promote survival in neurons and cancer cells , 2014, Science Signaling.
[109] D. Green,et al. Resistance to caspase-independent cell death requires persistence of intact mitochondria. , 2010, Developmental cell.
[110] R. Wood‐Baker,et al. BCL-2 Expression is Prognostic for Improved Survival in Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[111] Chao-Po Lin,et al. Role of apoptotic nuclease caspase-activated DNase in etoposide-induced treatment-related acute myelogenous leukemia. , 2006, Cancer research.
[112] S. Mañes,et al. CX3CL1 at the crossroad of EGF signals , 2013, Oncoimmunology.
[113] D. Green,et al. Die another way – non-apoptotic mechanisms of cell death , 2014, Journal of Cell Science.
[114] Xiao-Ming Yin,et al. Deletion of Bid impedes cell proliferation and hepatic carcinogenesis. , 2005, The American journal of pathology.
[115] T. Mitchison,et al. Prolonged mitotic arrest triggers partial activation of apoptosis, resulting in DNA damage and p53 induction , 2012, Molecular biology of the cell.
[116] M. Peter,et al. CD95 and CD95L promote and protect cancer stem cells , 2014, Nature Communications.
[117] Jian Yu,et al. PUMA–mediated apoptosis drives chemical hepatocarcinogenesis in mice , 2011, Hepatology.
[118] Jochen H M Prehn,et al. Systems analysis of effector caspase activation and its control by X‐linked inhibitor of apoptosis protein , 2006, The EMBO journal.
[119] R. Bejar,et al. Recent developments in myelodysplastic syndromes. , 2014, Blood.
[120] G. Gillet,et al. Non-apoptotic roles of Bcl-2 family: the calcium connection. , 2013, Biochimica et biophysica acta.
[121] A. Strasser,et al. Apoptosis-promoted tumorigenesis: gamma-irradiation-induced thymic lymphomagenesis requires Puma-driven leukocyte death. , 2010, Genes & development.
[122] Andreas Villunger,et al. p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa , 2003, Science.
[123] Erinna F. Lee,et al. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53 , 2014, Genes & development.
[124] L. Galluzzi,et al. Mitochondria as therapeutic targets for cancer chemotherapy , 2006, Oncogene.
[125] D. Gao,et al. Postpartum diagnosis demonstrates a high risk for metastasis and merits an expanded definition of pregnancy-associated breast cancer , 2013, Breast Cancer Research and Treatment.
[126] T. Taniguchi,et al. Apoptotic Caspases Prevent the Induction of Type I Interferons by Mitochondrial DNA , 2014, Cell.
[127] C. Knudson,et al. Lymphoma development in Bax transgenic mice is inhibited by Bcl-2 and associated with chromosomal instability , 2003, Cell Death and Differentiation.
[128] R. Pierce,et al. Bcl-2 expression inhibits liver carcinogenesis and delays the development of proliferating foci. , 2002, The American journal of pathology.
[129] D. Green,et al. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. , 2011, Molecular cell.
[130] M. Rehm,et al. Activity of protein kinase CK2 uncouples Bid cleavage from caspase-8 activation , 2010, Journal of Cell Science.
[131] H. Ford,et al. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics , 2013, Oncogene.
[132] J. Martinou,et al. TRAIL promotes membrane blebbing, detachment and migration of cells displaying a dysfunctional intrinsic pathway of apoptosis , 2012, Apoptosis.
[133] M. Kalmanti,et al. Enhanced levels of the apoptotic BAX/BCL-2 ratio in children with acute lymphoblastic leukemia and high-risk features , 2013, Genetics and molecular biology.
[134] C. Watson,et al. The complexity of the relationships between age at first birth and breast cancer incidence curves implicate pregnancy in cancer initiation as well as promotion of existing lesions. Preface. , 2009, Journal of mammary gland biology and neoplasia.
[135] J. Xiang,et al. BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[136] T. Chua,et al. Does the expression of BCL2 have prognostic significance in malignant peritoneal mesothelioma? , 2013, American journal of cancer research.
[137] Hui Sun,et al. Upregulation of fractalkine contributes to the proliferative response of prostate cancer cells to hypoxia via promoting the G1/S phase transition , 2015, Molecular medicine reports.
[138] L. Révész. Genetic Studies of the Relationship of Tumour–Host Cells: Effect of Tumour Cells killed by X-rays upon the Growth of Admixed Viable Cells , 1956, Nature.
[139] F. Gago,et al. Prognostic value of Bcl‐2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy , 2008, Molecular oncology.
[140] D. Hasenclever,et al. High Bad and Bax mRNA expression correlate with negative outcome in acute myeloid leukemia (AML) , 2002, Leukemia.
[141] R. Fietkau,et al. Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner , 2015, Cell Death and Disease.
[142] A. Marusyk,et al. Irradiation Selects for p53-Deficient Hematopoietic Progenitors , 2010, PLoS biology.
[143] A. Strasser,et al. Inhibition of apoptosis by BCL2 prevents leukemic transformation of a murine myelodysplastic syndrome. , 2012, Blood.
[144] David L. Vaux,et al. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells , 1988, Nature.
[145] Christina S. Leslie,et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression , 2013, Nature Medicine.
[146] Gerard I. Evan,et al. The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant , 2000, Nature Cell Biology.
[147] A. Azizzadeh Delshad,et al. Correlation between Apoptosis and Histological Grade of Transitional Cell Carcinoma of Urinary Bladder. , 2004, Urology journal.
[148] L. Wiesmüller,et al. Leukemogenic rearrangements at the mixed lineage leukemia gene (MLL)—multiple rather than a single mechanism , 2015, Front. Cell Dev. Biol..
[149] J. Blay,et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. , 2014, Cancer cell.
[150] David L. Vaux,et al. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies , 2016, Nature Reviews Cancer.
[151] Yali Dou,et al. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases , 2015, Nature Reviews Cancer.
[152] K. Ravichandran,et al. Phagocytosis of apoptotic cells in homeostasis , 2015, Nature Immunology.
[153] A. Letai,et al. Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy , 2011, Science.
[154] J. Cleveland,et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. , 2003, Cancer cell.